Abstract Library

#3223 Telemedicine: A good tool to improve health care in NEN´s patient during the COVID19 pandemic. A multicenter series experience of a NET multidisciplinary team in Argentina

Introduction: COVID-19 pandemic has infected nearly 55,078,170 individuals with 1,328,262 deaths since first identified in the human population in December 2019 in Wuhan, China. Global all-cause morbidity and mortality have increased due to the low availability of Global Health Care Services. The new challenge is to maintain high standards of care.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Oviedo A

Authors: Oviedo Albor A, Maquieria J, Eleta M, Rizzolo M, Basso S,

Keywords: telemedicine, covid-19, NETS, Argentina,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients

Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Childs A

Authors: Childs A, Vesely C, Rizzo F, Ensell L, Lowe H,

Keywords: CTCs, tumor heterogeneity, CNV,

#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)

Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rizzo F, Vesely C, Childs A, Mandair D, Khan M,

Keywords: CTC, CXCR4, bone,

#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series

Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pérez de la Puente C

Authors: Pérez de la Puente C, Mando P, Rizzo M, Rivero S, Pesce V,

Keywords: TNE, therapy target,